XRTX
Income statement / Annual
Last year (2023), XORTX Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, XORTX Therapeutics Inc.'s net income was -$2.15 M.
See XORTX Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
02/28/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$141,958.87
|
$75,268.00
|
$17,882.00
|
$20,439.00
|
$19,900.00
|
$19,316.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$141,958.87
|
-$75,268.00
|
-$17,882.00
|
-$20,439.00
|
-$19,900.00
|
-$19,316.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.41 M
|
$6.49 M
|
$669,106.00
|
$277,455.00
|
$39,897.00
|
$342,251.00
|
$66,367.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$1.07 M
|
$2.29 M
|
$1.58 M
|
$1.10 M
|
$506,168.00
|
$795,652.00
|
$380,922.00
|
$389,315.00
|
$36,922.00
|
| Selling & Marketing Expenses |
$1.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.39 M
|
$2.29 M
|
$1.58 M
|
$1.10 M
|
$506,168.00
|
$795,652.00
|
$380,922.00
|
$389,315.00
|
$36,922.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.64 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.81 M
|
$9.86 M
|
$2.86 M
|
$1.30 M
|
$565,965.00
|
$1.16 M
|
$464,066.00
|
$405,339.00
|
$36,922.00
|
| Cost And Expenses |
$4.81 M
|
$9.86 M
|
$2.86 M
|
$1.30 M
|
$565,965.00
|
$1.16 M
|
$464,066.00
|
$405,339.00
|
$36,922.00
|
| Interest Income |
$257,653.44
|
$101,366.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$4,390.52
|
$13,512.00
|
$37,214.00
|
$22,298.00
|
$15,463.00
|
$8,625.00
|
$0.00
|
| Depreciation & Amortization |
$141,958.87
|
$75,268.00
|
$17,882.00
|
$20,439.00
|
$19,900.00
|
$19,316.00
|
$16,777.00
|
$16,024.00
|
$0.00
|
| EBITDA |
-$4.87 M |
-$9.41 M |
-$1.63 M |
-$1.25 M |
-$572,465.00 |
-$1.07 M |
-$427,107.00 |
-$389,315.00 |
-$36,922.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.65 M
|
$2.95 M
|
$1.25 M
|
-$202,363.00
|
-$63,611.00
|
-$2.71 M
|
-$47,094.00
|
-$25,519.00
|
$0.00
|
| Income Before Tax |
-$2.15 M
|
-$6.99 M
|
-$1.30 M
|
-$1.28 M
|
-$629,576.00
|
-$3.78 M
|
-$474,201.00
|
-$414,834.00
|
-$36,922.00
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$4,390.52
|
$13,512.00
|
$37,214.00
|
$22,298.00
|
$10,087.00
|
$8,625.00
|
$0.00
|
| Net Income |
-$2.15 M
|
-$6.99 M
|
-$1.30 M
|
-$1.28 M
|
-$629,576.00
|
-$3.78 M
|
-$474,201.00
|
-$414,834.00
|
-$36,922.00
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.08 |
-4.72 |
-1.19 |
-1.73 |
-1.06 |
-6.45 |
-2.24 |
-2.05 |
-0.49 |
| EPS Diluted |
-1.08 |
-4.72 |
-1.19 |
-1.73 |
-1.06 |
-6.45 |
-2.24 |
-2.05 |
-0.49 |
| Weighted Average Shares Out |
$1.98 M
|
$1.48 M
|
$1.09 M
|
$740,447.00
|
$595,492.00
|
$584,988.00
|
$211,446.00
|
$202,742.00
|
$75,567.00
|
| Weighted Average Shares Out Diluted |
$1.98 M
|
$1.48 M
|
$1.09 M
|
$740,447.00
|
$595,492.00
|
$584,988.00
|
$211,446.00
|
$202,742.00
|
$75,567.00
|
| Link |
|
|
|
|
|
|
|
|
|
